Beckley Retreats Blog

Psilocybin and Alcohol: Can It Help Reduce Drinking?

Written by Jake Dickson | Jun 12, 2026 11:50:46 PM

Too many people think alcoholism means just liking booze a little too much. For some, that definitely contributes.

The root causes of alcoholism, according to leading scientists, aren’t that superficial - they start deep in the brain, and emerging research suggests alcoholic tendencies may start years before someone reaches the legal drinking age.

The causes of alcoholism are still under the microscope. But the consequences are clear:

  • 13% of men and 8% of women above age 18 have struggled with alcohol use disorder in the past year.
  • Excessive alcohol use shortens lifespan in addicts by an average 24 years.
  • Only about a third of people who are treated for AUD with current interventions have no symptoms a year later.

Scientists on the cutting edge of addiction research are exploring every would-be remedy. As of mid-2026, there are ongoing clinical trials looking at applying ultrasound to certain regions of the brain, identifying the roles of specific enzymes, or even testing the utility of GLP-1 drugs.

But what about psilocybin and alcohol? Is that not simply replacing one drug addiction for another? The answer - and the growing body of research on psychedelics as alternative therapies - might surprise you.

Understanding Alcohol Use Disorder

According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), alcohol use disorder is “an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences.” AUD is more commonly referred to as alcoholism.

The alcohol use disorders identification test, or AUDIT, has been used as a primary screen for AUD since 1989 and is based on foundational research into the condition. It assigns risk by placing users on a 40-point scale based on their replies to questions about:

  • Drinking frequency
  • Willpower to resist alcohol
  • Consequences related to alcohol intake

Anyone who scores 8/40 or above is recommended to take action related to their drinking habits. Score above a 20 and you’re put into the “severe” category, where alcoholism is both life-disruptive and potentially life-threatening.

Psilocybin and Alcohol: Why Researchers Are Curious

Scientists believe conditions like AUD are rooted in neural dysfunction - something amiss in the brain, such as a chemical imbalance, or, more likely, crucial reward circuitry is tangled up, preventing the brain from appropriately managing urges.

AUD sufferers don’t seek alcohol because they find it more palatable than most people. They are, at the neurological level, compelled to do so. Addressing that deep compulsion is the goal of contemporary addiction science. It’s why there's an investigation into psilocybin and alcohol use disorder.

Psilocybin - known colloquially as magic mushrooms - is a classic psychedelic. Beyond making you trip for a few hours, we’ve learned that psilocybin promotes neuroplasticity, which underpins the brain’s ability to rewire maladaptive pathways.

The neuroplastic window is a cornerstone of psychedelic-assisted therapy (PAT), which people seek as a way of escaping mental illness or refreshing their perspective on life. As it turns out, opening the neuroplastic window may help addicts escape their addictions, too.

We’re already seeing promise in rodent studies, where psilocybin seems to enhance “crosstalk” between neurotransmitters and “modulate reward and addiction-related behaviors.” Human research, however, is more complicated.

Psilocybin and Alcohol: What the Research Says

The regulatory reins around psychedelic research are finally beginning to loosen. Researchers are diving into the therapeutic potential of psychedelics for the treatment of all sorts of afflictions, including but not limited to alcohol use disorder.

So far, the findings are promising but far from conclusive.

There were “robust decreases” in the number of heavy drinking days among 93 alcoholics that persisted for more than six months after undergoing psilocybin-assisted therapy (PAT), according to a 2022 trial.

Psilocybin “durably suppressed” personality traits associated with AUD compared to patients who were given a placebo (diphenhydramine, an allergy medication) during 12 weeks of psychotherapy, per trial data.

“Quantum change” from psychedelic-induced “mystical experiences” may drive AUD sufferers away from the desire to drink, researchers say.

Scientists and institutions are examining the interactions between psilocybin and alcohol from different angles. What do their works have in common? A call for more research.

Initial findings are extremely encouraging. Psilocybin and alcohol seem to be intertwined, and taking psilocybin might help manage alcoholism, according to the few large-scale systematic reviews available. Comprehensive, peer-reviewed evidence is what leads to updated position stands and policy changes.

In the interim, alcoholics and other addicts are turning to both clinical PAT and psychedelic retreats for relief, where teams of facilitators guide guests through psychedelic experiences and help them harness lasting change through proper integration practices.

Frequently Asked Questions

Sources

  1. Anderson LG, Tischer AE, Bock R, Michaelides M, Alvarez VA. Early life adversity increases striatal dopamine D1 receptor density and promotes social alcohol drinking in mice, especially males. Transl Psychiatry. 2026 Apr 15;16(1):278. doi: 10.1038/s41398-026-04033-2. PMID: 41986313; PMCID: PMC13194699.
  2. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality (CBHSQ). 2024 National Survey on Drug Use and Health. Table 5.9A—Alcohol use disorder in past year: among people aged 12 or older; by age group and demographic characteristics, numbers in thousands, 2023 and 2024.
  3. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804. doi: 10.1111/j.1360-0443.1993.tb02093.x. PMID: 8329970.
  4. Maki KA, Wallen GR, Bastiaanssen TFS, Hsu LY, Valencia ME, Ramchandani VA, Schwandt ML, Diazgranados N, Cryan JF, Momenan R, Barb JJ. The gut-brain axis in individuals with alcohol use disorder: An exploratory study of associations among clinical symptoms, brain morphometry, and the gut microbiome. Alcohol Clin Exp Res (Hoboken). 2024 Jul;48(7):1261-1277. doi: 10.1111/acer.15346. Epub 2024 Jun 22. PMID: 38982564; PMCID: PMC11239122.
  5. Adeyinka D, Forsyth D, Currie S and Faraone N (2025) Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models. Front. Syst. Neurosci. 19:1585367. doi: 10.3389/fnsys.2025.1585367
  6. Kishon R, Cycowicz YM. Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes. Front Psychiatry. 2025 Sep 1;16:1637162. doi: 10.3389/fpsyt.2025.1637162. PMID: 40958789; PMCID: PMC12434020.
  7. Omidian, H.; Omidian, A. The Emergence of Psilocybin in Psychiatry and Neuroscience. Pharmaceuticals 2025, 18, 555. https://doi.org/10.3390/ph18040555
  8. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953–962. doi:10.1001/jamapsychiatry.2022.2096
  9. Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, O'Donnell KC, Ross S, Bogenschutz MP. Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial. Am J Psychiatry. 2025 Jan 1;182(1):114-125. doi: 10.1176/appi.ajp.20230887. PMID: 39741446.
  10. Jensen ME, Stenbæk DS, Juul TS, Fisher PM, Ekstrøm CT, Knudsen GM, Fink-Jensen A. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). BMJ Open. 2022 Oct 14;12(10):e066019. doi: 10.1136/bmjopen-2022-066019. PMID: 36241352; PMCID: PMC9577917.
  11. Calleja-Conde J, Morales-García JA, Echeverry-Alzate V, Bühler KM, Giné E, López-Moreno JA. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. Addict Biol. 2022 Nov;27(6):e13229. doi: 10.1111/adb.13229. PMID: 36301215; PMCID: PMC9541961.